Cargando…

ET-7 EVALUATION OF HYPOXIA-TARGETING RADIOPHARMACEUTICAL(64)CU-ATSM FOR PET MONITORING WITH LOCAL THERAPY IN HIGH-GRADE GLIOMA MODEL

World Health Organization (WHO)-defined central nervous system (CNS) grade 4 high-grade gliomas (HGGs) are highly aggressive brain cancers characterized by the presence of hypoxia within a rapidly-growing tumor mass. Due to invasion to the surrounding brain parenchyma, these tumors commonly recur lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshii, Yukie, Hihara, Fukiko, Matsumoto, Hiroki, Igarashi, Chika, Tachibana, Tomoko, Shinada, Mitsuhiro, Ming-Rong, Zhang, Oshima, Akito, Sato, Hidemitsu, Narita, Yoshitaka, Kurihara, Hiroaki, Yamamoto, Tetsuya, Higashi, Tatsuya, Tateishi, Kensuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719295/ http://dx.doi.org/10.1093/noajnl/vdac167.019

Ejemplares similares

Process to Remove the Size Variants Contained in the Antibody–Chelator Complex PCTA-NCAB001 for Radiolabeling with Copper-64
por: Yoshii, Yukie, et al.
Publicado: (2023)

Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET
por: Matsumoto, Hiroki, et al.
Publicado: (2022)

In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized (64)Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study
por: Hihara, Fukiko, et al.
Publicado: (2022)

Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free (225)Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy
por: Yoshimoto, Mitsuyoshi, et al.
Publicado: (2021)

Characterization and Stabilization of a New (64)Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography
por: Matsumoto, Hiroki, et al.
Publicado: (2021)

Multiple Administrations of (64)Cu-ATSM as a Novel Therapeutic Option for Glioblastoma: a Translational Study Using Mice with Xenografts
por: Yoshii, Yukie, et al.
Publicado: (2017)

Evaluation of (64)Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates
por: Matsumoto, Hiroki, et al.
Publicado: (2021)

(64)Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts
por: Yoshii, Yukie, et al.
Publicado: (2017)

Validation of (64)Cu-ATSM damaging DNA via high-LET Auger electron emission
por: McMillan, Dayton D., et al.
Publicado: (2015)

Controlled Administration of Penicillamine Reduces Radiation Exposure in Critical Organs during (64)Cu-ATSM Internal Radiotherapy: A Novel Strategy for Liver Protection
por: Yoshii, Yukie, et al.
Publicado: (2014)

(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
por: Hansen, Anders E, et al.
Publicado: (2012)

Preclinical Pharmacokinetic and Safety Studies of Copper-Diacetyl-Bis(N(4)-Methylthiosemicarbazone) (Cu-ATSM): Translational Studies for Internal Radiotherapy
por: Matsumoto, Hiroki, et al.
Publicado: (2019)

Uniform intratumoral distribution of radioactivity produced using two different radioagents, (64)Cu-cyclam-RAFT-c(-RGDfK-)(4) and (64)Cu-ATSM, improves therapeutic efficacy in a small animal tumor model
por: Jin, Zhao-Hui, et al.
Publicado: (2018)

Immuno-OpenPET: a novel approach for early diagnosis and image-guided surgery for small resectable pancreatic cancer
por: Yoshii, Yukie, et al.
Publicado: (2020)

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study
por: Pérès, Elodie A., et al.
Publicado: (2019)

Pharmacokinetic Analysis of (64)Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice
por: Li, Fan, et al.
Publicado: (2015)

Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging
por: Colombié, Mathilde, et al.
Publicado: (2015)

Modification of intracellular glutathione status does not change the cardiac trapping of (64)Cu(ATSM)
por: Shaughnessy, Fiona, et al.
Publicado: (2014)

(64)Cu-ATSM Predicts Efficacy of Carbon Ion Radiotherapy Associated with Cellular Antioxidant Capacity
por: Nachankar, Ankita, et al.
Publicado: (2021)

(64)Cu-based Radiopharmaceuticals in Molecular Imaging
por: Zhou, Yeye, et al.
Publicado: (2019)

Pre-clinical Positron Emission Tomography Reconstruction Algorithm Effect on Cu-64 ATSM Lesion Hypoxia
por: Sanghera, Bal, et al.
Publicado: (2016)

64Cu-ATSM Hypoxia Positron Emission Tomography for Detection of Conduit Ischemia in an Experimental Rat Esophagectomy Model
por: Park, Seong Yong, et al.
Publicado: (2015)

Tissue acidosis does not mediate the hypoxia selectivity of [(64)Cu][Cu(ATSM)] in the isolated perfused rat heart
por: Baark, Friedrich, et al.
Publicado: (2019)

Development of an automated production process of [(64)Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications
por: Liu, Tengzhi, et al.
Publicado: (2022)

Assessment of the Tumor Redox Status in Head and Neck Cancer by (62)Cu-ATSM PET
por: Tsujikawa, Tetsuya, et al.
Publicado: (2016)

Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals
por: Krasnovskaya, Olga O., et al.
Publicado: (2023)

Impact of [(64)Cu][Cu(ATSM)] PET/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report
por: Gangemi, Vincenzo, et al.
Publicado: (2019)

Cerebral Oxidative Stress in Early Alzheimer’s Disease Evaluated by (64)Cu-ATSM PET/MRI: A Preliminary Study
por: Okazawa, Hidehiko, et al.
Publicado: (2022)

Cu(II)(atsm) Attenuates Neuroinflammation
por: Choo, Xin Yi, et al.
Publicado: (2018)

Feasibility of Renal Blood Flow Measurement Using (64)Cu-ATSM PET/MRI: A Quantitative PET and MRI Study
por: Nishikawa, Yudai, et al.
Publicado: (2023)

Evaluation of hypoxia in a feline model of head and neck cancer using (64)Cu-ATSM positron emission tomography/computed tomography
por: Ballegeer, Elizabeth A, et al.
Publicado: (2013)

Estimation of biological effect of Cu-64 radiopharmaceuticals with Geant4-DNA simulation
por: Kusumoto, Tamon, et al.
Publicado: (2022)

Increasing Reaction Rates of Water-Soluble Porphyrins for (64)Cu Radiopharmaceutical Labeling
por: Pęgier, Mateusz, et al.
Publicado: (2023)

Assessment of hypoxia and oxidative-related changes in a lung-derived brain metastasis model by [(64)Cu][Cu(ATSM)] PET and proteomic studies
por: Fantin, Jade, et al.
Publicado: (2023)

The Efficient Synthesis and Biological Evaluation of Novel Bi-Functionalized Sarcophagine for (64)Cu Radiopharmaceuticals
por: Liu, Shuanglong, et al.
Publicado: (2012)

CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits
por: Vieira, Fernando G., et al.
Publicado: (2017)

Micro Regional Heterogeneity of (64)Cu-ATSM and (18)F-FDG Uptake in Canine Soft Tissue Sarcomas: Relation to Cell Proliferation, Hypoxia and Glycolysis
por: Zornhagen, Kamilla Westarp, et al.
Publicado: (2015)

Hypoxia imaging and theranostic potential of [(64)Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms
por: Liu, Tengzhi, et al.
Publicado: (2020)

Cellular Uptake of the ATSM−Cu(II) Complex under Hypoxic Conditions
por: Walke, Gulshan R., et al.
Publicado: (2021)

Evaluation of (64)Cu-Based Radiopharmaceuticals that Target Aβ Peptide Aggregates as Diagnostic Tools for Alzheimer’s Disease
por: Bandara, Nilantha, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nd642cv1i6c8ldpevnnerm60nv